Metastatic Prostate Cancer

What is Metastatic Prostate Cancer?

Metastatic prostate cancer occurs when prostate cancer cells spread beyond the prostate gland to other parts of the body. The cancer most commonly spreads to bones, particularly the spine, pelvis, ribs, and hips. It can also spread to lymph nodes, liver, lungs, and other organs.

This is the most advanced stage of prostate cancer, also called stage 4 or stage IV. When cancer spreads, it forms new tumors but remains prostate cancer at the cellular level. These distant tumors are called metastases. Metastatic prostate cancer is not curable, but many men live for years with treatment that slows disease progression and manages symptoms.

Regular monitoring with PSA blood tests helps doctors track how well treatment is working. PSA stands for prostate-specific antigen, a protein produced by prostate cells. Markedly elevated PSA levels, often above 20 to 100 ng/mL, are associated with metastatic disease. Rising PSA levels despite treatment may signal that the cancer is progressing or becoming resistant to therapy.

Prostate-Specific Antigen (PSA), Free and Total (MALES ONLY)

Measures total and free PSA
Adds percent-free PSA to your total result
More context when a total PSA needs a closer look

^$74

Male Deluxe Checkup

Pinpoint the cause of low energy
Reveal hidden issues affecting your performance
Assess your heart health comprehensively

^$107

Deluxe Men's Cancer Profile

Detect early signs of cancer effortlessly
Reveal hidden health risks with precision
Confirm your overall wellness confidently

^$158

Symptoms

Bone pain, especially in the back, hips, ribs, or pelvis
Fractures or bones that break easily
Difficulty urinating or weak urine stream
Blood in urine or semen
Persistent fatigue and weakness
Unexplained weight loss
Loss of appetite
Swelling in legs or feet
Numbness or weakness in legs or feet
Loss of bladder or bowel control

Some men have no symptoms in early metastatic disease. Bone pain is often the first noticeable symptom as cancer spreads to the skeleton. Symptoms depend on where the cancer has spread and how much it has grown.

Causes and risk factors

Metastatic prostate cancer develops when localized prostate cancer is not detected early or does not respond to initial treatment. Cancer cells break away from the original prostate tumor and travel through the bloodstream or lymphatic system to distant sites. Age is the strongest risk factor, with most cases occurring in men over 65. Family history of prostate cancer doubles or triples risk, especially if a father or brother was diagnosed before age 60.

Black men have higher rates of prostate cancer and are more likely to develop aggressive disease that spreads. Genetic mutations, including BRCA1, BRCA2, and Lynch syndrome genes, increase risk of aggressive prostate cancer. Obesity, smoking, and diets high in red meat and dairy may contribute to cancer progression. Men with advanced prostate cancer at initial diagnosis face higher risk of metastasis.

How it's diagnosed

Metastatic prostate cancer is diagnosed through a combination of imaging studies and blood tests. PSA blood testing is essential for monitoring disease burden and treatment response. Markedly elevated PSA levels, often ranging from 20 to 100 ng/mL or higher, suggest metastatic disease. Rite Aid offers PSA testing as an add-on to help you monitor prostate health and track treatment progress.

Doctors also use bone scans, CT scans, MRI, and PET scans to identify where cancer has spread. A biopsy of the original prostate tumor provides information about cancer grade and aggressiveness. Once metastatic disease is confirmed, PSA tests are repeated regularly to assess whether treatment is working. Rising PSA levels despite therapy indicate disease progression or treatment resistance.

Treatment options

Androgen deprivation therapy to lower testosterone levels that fuel cancer growth
Chemotherapy drugs like docetaxel or cabazitaxel for advanced disease
Newer hormone therapies such as abiraterone, enzalutamide, or darolutamide
Radiation therapy to relieve bone pain and slow tumor growth
Bone-strengthening medications to prevent fractures
PARP inhibitors for men with BRCA or other gene mutations
Immunotherapy in select cases
Pain management and supportive care
Regular PSA monitoring to track treatment response
Healthy diet with plenty of vegetables, fruits, and whole grains
Regular physical activity to maintain strength and reduce fatigue
Stress management and mental health support

Frequently asked questions

Prostate cancer that stays within the prostate gland is localized and often curable with surgery or radiation. Metastatic prostate cancer has spread beyond the prostate to other organs or bones. Metastatic disease is not curable but can be managed with treatment for many years.

Survival varies widely based on many factors including age, overall health, cancer aggressiveness, and treatment response. Some men live 2 to 3 years, while others live 5 to 10 years or longer with effective treatment. New therapies continue to improve outcomes and extend survival for many patients.

PSA levels above 20 to 100 ng/mL often indicate metastatic disease with significant cancer burden. Very high PSA suggests more extensive spread, particularly to bones. Regular PSA testing helps track whether your treatment is working or if the cancer is progressing.

Metastatic prostate cancer is generally not curable because cancer cells have spread to distant parts of the body. However, many effective treatments can slow disease progression, shrink tumors, relieve symptoms, and extend survival. Some men live for many years with good quality of life on treatment.

Prostate cancer most commonly spreads to bones, especially the spine, pelvis, hips, and ribs. The lymph nodes near the prostate are often the first site of spread. Less commonly, it can spread to the liver, lungs, or brain.

Most oncologists check PSA levels every 1 to 3 months during active treatment. More frequent testing helps doctors quickly identify if treatment is working or if PSA is rising. Rising PSA despite treatment signals disease progression and may prompt a change in therapy.

Bone pain occurs when cancer cells invade bone tissue and trigger inflammation. The cancer can weaken bones and cause small fractures or compression of nerves. Bone pain is often the first symptom men notice when prostate cancer spreads to the skeleton.

Androgen deprivation therapy lowers testosterone, which can cause hot flashes, fatigue, weight gain, and loss of muscle mass. Many men experience reduced sex drive and erectile dysfunction. Long-term use can weaken bones, increase diabetes risk, and affect mood and memory.

While diet and lifestyle cannot cure metastatic cancer, they can support overall health and treatment tolerance. Regular exercise helps maintain strength and reduce fatigue. Eating plenty of vegetables, fruits, and whole grains while limiting red meat and processed foods may support better outcomes.

Rising PSA levels after an initial decrease suggest the cancer is progressing or becoming resistant to current treatment. This is called biochemical progression or PSA progression. Your doctor will likely recommend imaging tests and may change your treatment plan to a different therapy.